A detailed history of Bank Of America Corp transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Bank Of America Corp holds 210,677 shares of VRDN stock, worth $5.11 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
210,677
Previous 475,733 55.72%
Holding current value
$5.11 Million
Previous $8.33 Million 67.11%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$11.6 - $17.26 $3.07 Million - $4.57 Million
-265,056 Reduced 55.72%
210,677 $2.74 Million
Q1 2024

May 15, 2024

BUY
$17.09 - $23.82 $3.23 Million - $4.51 Million
189,285 Added 66.08%
475,733 $8.33 Million
Q4 2023

Feb 14, 2024

BUY
$11.12 - $22.5 $1.2 Million - $2.42 Million
107,697 Added 60.25%
286,448 $6.24 Million
Q2 2023

Aug 14, 2023

SELL
$22.57 - $29.67 $1.72 Million - $2.26 Million
-76,070 Reduced 29.85%
178,751 $4.25 Million
Q1 2023

May 12, 2023

BUY
$25.04 - $37.6 $3.49 Million - $5.24 Million
139,443 Added 120.86%
254,821 $6.48 Million
Q4 2022

Feb 10, 2023

BUY
$18.78 - $29.74 $1.1 Million - $1.75 Million
58,682 Added 103.5%
115,378 $3.37 Million
Q3 2022

Nov 14, 2022

BUY
$10.7 - $25.5 $481,146 - $1.15 Million
44,967 Added 383.38%
56,696 $1.16 Million
Q2 2022

Aug 12, 2022

SELL
$9.55 - $19.0 $58,293 - $115,976
-6,104 Reduced 34.23%
11,729 $135,000
Q1 2022

May 16, 2022

BUY
$16.79 - $20.88 $139,676 - $173,700
8,319 Added 87.44%
17,833 $330,000
Q4 2021

Feb 08, 2022

BUY
$15.65 - $21.5 $146,186 - $200,831
9,341 Added 5399.42%
9,514 $188,000
Q3 2021

Nov 15, 2021

BUY
$10.69 - $18.2 $1,849 - $3,148
173 New
173 $3,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $968M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.